EBITDA (Quarterly)

EBITDA: Income before interest, taxes, depreciation and amortization.

BioXcel Therapeutics, Inc. (BTAI) had EBITDA of $-10.16M for the most recently reported fiscal quarter, ending 2026-03-31.

Quarterly Annual

Figures for fiscal quarter ending 2026-03-31

Income Statement Financials
Revenue	$0.21M
Net Income	$-12.69M
Cost of Goods Sold	$0.28M
Gross Profit	$-0.08M
Operating Expenses	$10.43M
Operating Income	$-10.22M
Non-Operating Income/Expense	$-2.47M
Pre-Tax Income	$-12.69M
Normalized Pre-Tax Income	$-12.69M
Income after Taxes	$-12.69M
Income from Continuous Operations	$-12.69M
Consolidated Net Income/Loss	$-12.69M
Normalized Income after Taxes	$-12.69M
EBIT	$-10.22M
EBITDA	$-10.16M
Weighted-Average Shares Outstanding (Basic)	23.57M
Weighted-Average Shares Outstanding (Diluted)	23.57M
Earnings per Share (EPS) (Basic)	$-0.54
Earnings per Share (EPS) (Diluted)	$-0.54
Balance Sheet Financials
Current Assets	$33.91M
Property, Plant, and Equipment	$0.12M
Long-Term Assets	$0.12M
Total Assets	$34.02M
Current Liabilities	$54.99M
Long-Term Debt	$77.86M
Long-Term Liabilities	$84.57M
Total Liabilities	$139.57M
Common Equity	$-105.54M
Tangible Shareholders Equity	$-105.54M
Shareholders Equity	$-105.54M
Common Shares Outstanding	27.07M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-11.81M
Cash Flow from Investing Activities	--
Cash Flow from Financial Activities	$0.23M
Beginning Cash	$28.76M
End Cash	$17.18M
Increase/Decrease in Cash	$-11.58M
Stock-Based Compensation	$0.43M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	0.62
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-2.81
Debt to Equity Ratio	-0.95
Gross Margin	-37.38%
Operating Margin	-4962.62%
EBIT Margin	-4962.62%
EBITDA Margin	--
Pre-Tax Profit Margin	-6160.68%
Profit Margin	-6160.68%
Free Cash Flow	$-11.81M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.01
Inventory Turnover	0.57
Receiveable Turnover	0.95
Days Sales in Receivables	94.37
Return on Equity	12.02%
Return on Tangible Equity	12.02%
Return on Assets	-37.30%
Return on Investments	45.84%
Book Value Per Share	$-3.90
Free Cash Flow per Share	$-0.50
Operating Cash Flow per Share	$-0.50

Data from Zacks Investment Research, Inc.